Similar to what has been described in metabolic disorders (Rossmeisl et al, 2003; Thaler et al, 2013), i.c.v.-injected AβOs induce adipose tissue inflammation and impaired insulin-induced surface translocation of GLUT-4 in muscle cells. Here, SLC2A4 is linked to metabolic disease.